Back to results
US 2026/0287590 A1Published application
Methods for differentiating benign prostatic hyperplasia from prostate cancer
AssigneeBPGbio, Inc.
InventorsMichael Andrew Kiebish, Poornima Tekumalla, Niven Rajin Narain, Rangaprasad Sarangarajan
Life of this patent
Estimating the term…
Abstract
Methods for differentiating between benign prostatic hyperplasia (BPH) and prostate cancer, in a subject, are provided, such methods including the detection of levels of one or more biomarker diagnostic of BPH. The invention also provides a kit for the diagnosis of BPH, without the need for a biopsy.
Claims9
-96. (canceled)
A method for treating benign prostatic hyperplasia (BPH), comprising:
- (a) detecting the protein level of Filamin A (FLNA) in a biological sample from a subject;
- (b) obtaining measurement of prostate volume of the subject;
- (c) producing a score on the basis of the detected level of FLNA in the sample in combination with the age and prostate volume of the subject, wherein the score is not produced on the basis of the level of keratin 19 (KRT19);
- (d) identifying the subject to have BPH when the score is below a threshold score;
- and
- (e) administering to the subject a therapeutic treatment for BPH, wherein the therapeutic treatment comprises a selective al-blocker, a 5α-reductase inhibitor, an antimuscarinic, a phosphodiesterase-5 inhibitor, a surgery, a prostatic stent, a high intensity focused ultrasound, an interstitial laser coagulation, a transurethral electroevaporation of the prostate, a transurethral microwave thermotherapy, a transurethral needle ablation, a photoselective vaporization, or a combination thereof.
3 more elements
Dependencies are inferred from the claim text.